Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Cash from Investing Activities (2020 - 2024)

Historic Cash from Investing Activities for HCW Biologics (HCWB) over the last 5 years, with Q4 2024 value amounting to -$113412.0.

  • HCW Biologics' Cash from Investing Activities rose 9694.77% to -$113412.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$113412.0, marking a year-over-year increase of 9706.48%. This contributed to the annual value of -$261617.0 for FY2024, which is 10688.94% down from last year.
  • As of Q4 2024, HCW Biologics' Cash from Investing Activities stood at -$113412.0, which was up 9694.77% from -$37063.0 recorded in Q3 2024.
  • In the past 5 years, HCW Biologics' Cash from Investing Activities registered a high of $9.4 million during Q3 2023, and its lowest value of -$35.0 million during Q3 2021.
  • Over the past 5 years, HCW Biologics' median Cash from Investing Activities value was -$37063.0 (recorded in 2024), while the average stood at -$995079.2.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 3313835.19% in 2021, then soared by 3436386.87% in 2022.
  • Quarter analysis of 5 years shows HCW Biologics' Cash from Investing Activities stood at -$36391.0 in 2020, then skyrocketed by 34.31% to -$23904.0 in 2021, then tumbled by 187.35% to -$68687.0 in 2022, then tumbled by 5309.54% to -$3.7 million in 2023, then surged by 96.95% to -$113412.0 in 2024.
  • Its Cash from Investing Activities was -$113412.0 in Q4 2024, compared to -$37063.0 in Q3 2024 and $18567.0 in Q2 2024.